EPHB4 and chronic myelogenous leukemia, BCR-ABL1 positive: Recent reports show that EPHB4 is highly expressed in K562 cells [10, 18], and high expression of EPHB4 is associated with imatinib and dasatinib resistance [9, 17, 19], suggesting that EPHB4 may represent a potential target for CML therapy.